1
|
Katiraei S, de Vries MR, Costain AH, Thiem K, Hoving LR, van Diepen JA, Smits HH, Bouter KE, Rensen PCN, Quax PHA, Nieuwdorp M, Netea MG, de Vos WM, Cani PD, Belzer C, van Dijk KW, Berbée JFP, van Harmelen V. Akkermansia muciniphila Exerts Lipid-Lowering and Immunomodulatory Effects without Affecting Neointima Formation in Hyperlipidemic APOE*3-Leiden.CETP Mice. Mol Nutr Food Res 2020; 64:e1900732. [PMID: 31389129 PMCID: PMC7507188 DOI: 10.1002/mnfr.201900732] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Indexed: 12/21/2022]
Abstract
SCOPE Akkermansia muciniphila (A. muciniphila) is an intestinal commensal with anti-inflammatory properties both in the intestine and other organs. The aim is to investigate the effects of oral administration of A. muciniphila on lipid metabolism, immunity, and cuff-induced neointima formation in hyperlipidemic APOE*3-Leiden (E3L).CETP mice. METHODS AND RESULTS Hyperlipidemic male E3L.CETP mice are daily treated with 2 × 108 CFU A. muciniphila by oral gavage for 4 weeks and the effects are determined on plasma lipid levels, immune parameters, and cuff-induced neointima formation and composition. A. muciniphila administration lowers body weight and plasma total cholesterol and triglycerides levels. A. muciniphila influences the immune cell composition in mesenteric lymph nodes, as evident from an increased total B cell population, while reducing the total T cell and neutrophil populations. Importantly, A. muciniphila reduces the expression of the activation markers MHCII on dendritic cells and CD86 on B cells. A. muciniphila also increases whole blood ex vivo lipopolysaccharide-stimulated IL-10 release. Finally, although treatment with A. muciniphila improves lipid metabolism and immunity, it does not affect neointima formation or composition. CONCLUSIONS Four weeks of treatment with A. muciniphila exerts lipid-lowering and immunomodulatory effects, which are insufficient to inhibit neointima formation in hyperlipidemic E3L.CETP mice.
Collapse
Affiliation(s)
- Saeed Katiraei
- Department of Human GeneticsLeiden University Medical Center2300 RCLeidenThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Margreet R. de Vries
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
- Department of SurgeryLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Alice H. Costain
- Department of ParasitologyLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Kathrin Thiem
- Department of Internal MedicineRadboud UMC6525 GANijmegenThe Netherlands
| | - Lisa R. Hoving
- Department of Human GeneticsLeiden University Medical Center2300 RCLeidenThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
| | | | - Hermelijn H. Smits
- Department of ParasitologyLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Kristien E. Bouter
- Department of Vascular MedicineAcademic Medical Center1105 AZAmsterdamThe Netherlands
| | - Patrick C. N. Rensen
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
- Department of Medicinedivision of EndocrinologyLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Paul H. A. Quax
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
- Department of SurgeryLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Max Nieuwdorp
- Department of Vascular MedicineAcademic Medical Center1105 AZAmsterdamThe Netherlands
| | - Mihai G. Netea
- Department of Internal MedicineRadboud UMC6525 GANijmegenThe Netherlands
| | - Willem M. de Vos
- Laboratory of MicrobiologyWageningen University6708 WEWageningenThe Netherlands
| | - Patrice D. Cani
- Université catholique de LouvainLouvain Drug Research InstituteWELBIO (Walloon Excellence in Life sciences and BIOtechnology)Metabolism and Nutrition Research Group1200BrusselsBelgium
| | - Clara Belzer
- Laboratory of MicrobiologyWageningen University6708 WEWageningenThe Netherlands
| | - Ko Willems van Dijk
- Department of Human GeneticsLeiden University Medical Center2300 RCLeidenThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
- Department of Medicinedivision of EndocrinologyLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Jimmy F. P. Berbée
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
- Department of Medicinedivision of EndocrinologyLeiden University Medical Center2333 ZALeidenThe Netherlands
| | - Vanessa van Harmelen
- Department of Human GeneticsLeiden University Medical Center2300 RCLeidenThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical Center2333 ZALeidenThe Netherlands
| |
Collapse
|
2
|
Hoving LR, Katiraei S, Pronk A, Heijink M, Vonk KKD, Amghar-El Bouazzaoui F, Vermeulen R, Drinkwaard L, Giera M, van Harmelen V, Willems van Dijk K. The prebiotic inulin modulates gut microbiota but does not ameliorate atherosclerosis in hypercholesterolemic APOE*3-Leiden.CETP mice. Sci Rep 2018; 8:16515. [PMID: 30409998 PMCID: PMC6224586 DOI: 10.1038/s41598-018-34970-y] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Accepted: 10/26/2018] [Indexed: 12/22/2022] Open
Abstract
Gut microbiota have been implicated in the development of atherosclerosis and cardiovascular disease. Since the prebiotic inulin is thought to beneficially affect gut microbiota, we aimed to determine the effect of inulin supplementation on atherosclerosis development in APOE*3-Leiden.CETP (E3L.CETP) mice. Female E3L.CETP mice were fed a western-type diet containing 0.1% or 0.5% cholesterol with or without 10% inulin. The effects of inulin were determined on: microbiota composition, cecal short-chain fatty acid (SCFA) levels, plasma lipid levels, atherosclerosis development, hepatic morphology and hepatic inflammation. Inulin with 0.5% dietary cholesterol increased specific bacterial genera and elevated levels of cecal SCFAs, but did not affect plasma cholesterol levels or atherosclerosis development. Surprisingly, inulin resulted in mild hepatic inflammation as shown by increased expression of inflammation markers. However, these effects were not accompanied by increased hepatic macrophage number. Analogously, inulin induced mild steatosis and increased hepatocyte size, but did not affect hepatic triglyceride content. Inulin with 0.1% dietary cholesterol did not affect hepatic morphology, nor hepatic expression of inflammation markers. Overall, inulin did not reduce hypercholesterolemia or atherosclerosis development in E3L.CETP mice despite showing clear prebiotic activity, but resulted in manifestations of hepatic inflammation when combined with a high percentage of dietary cholesterol.
Collapse
Affiliation(s)
- Lisa R Hoving
- Department of Human Genetics, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands. .,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands.
| | - Saeed Katiraei
- Department of Human Genetics, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands
| | - Amanda Pronk
- Department of Human Genetics, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands
| | - Marieke Heijink
- Center for Proteomics and Metabolomics, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands
| | - Kelly K D Vonk
- Department of Human Genetics, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands
| | | | - Rosalie Vermeulen
- Department of Human Genetics, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands
| | - Lizette Drinkwaard
- Department of Human Genetics, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands
| | - Martin Giera
- Center for Proteomics and Metabolomics, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands
| | - Vanessa van Harmelen
- Department of Human Genetics, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands
| | - Ko Willems van Dijk
- Department of Human Genetics, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands. .,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands. .,Department of Medicine, division Endocrinology, Leiden University Medical Center (LUMC), 2300 RC, Leiden, The Netherlands.
| |
Collapse
|
3
|
Wang Y, Li Z, Yi C, Katiraei S, Kooijman S, Zhou E, Chung C, Gao Y, van den Heuvel J, Meijer O, Berbée J, Heijink M, Giera M, Willems van Dijk J, Groen A, Rensen P. Butyrate via the gut-brain neural circuit reduces appetite and activates brown adipose tissue. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.928] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
4
|
Li Z, Yi CX, Katiraei S, Kooijman S, Zhou E, Chung CK, Gao Y, van den Heuvel JK, Meijer OC, Berbée JFP, Heijink M, Giera M, Willems van Dijk K, Groen AK, Rensen PCN, Wang Y. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut 2018; 67:1269-1279. [PMID: 29101261 DOI: 10.1136/gutjnl-2017-314050] [Citation(s) in RCA: 345] [Impact Index Per Article: 57.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 10/20/2017] [Accepted: 10/23/2017] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Butyrate exerts metabolic benefits in mice and humans, the underlying mechanisms being still unclear. We aimed to investigate the effect of butyrate on appetite and energy expenditure, and to what extent these two components contribute to the beneficial metabolic effects of butyrate. DESIGN Acute effects of butyrate on appetite and its method of action were investigated in mice following an intragastric gavage or intravenous injection of butyrate. To study the contribution of satiety to the metabolic benefits of butyrate, mice were fed a high-fat diet with butyrate, and an additional pair-fed group was included. Mechanistic involvement of the gut-brain neural circuit was investigated in vagotomised mice. RESULTS Acute oral, but not intravenous, butyrate administration decreased food intake, suppressed the activity of orexigenic neurons that express neuropeptide Y in the hypothalamus, and decreased neuronal activity within the nucleus tractus solitarius and dorsal vagal complex in the brainstem. Chronic butyrate supplementation prevented diet-induced obesity, hyperinsulinaemia, hypertriglyceridaemia and hepatic steatosis, largely attributed to a reduction in food intake. Butyrate also modestly promoted fat oxidation and activated brown adipose tissue (BAT), evident from increased utilisation of plasma triglyceride-derived fatty acids. This effect was not due to the reduced food intake, but explained by an increased sympathetic outflow to BAT. Subdiaphragmatic vagotomy abolished the effects of butyrate on food intake as well as the stimulation of metabolic activity in BAT. CONCLUSION Butyrate acts on the gut-brain neural circuit to improve energy metabolism via reducing energy intake and enhancing fat oxidation by activating BAT.
Collapse
Affiliation(s)
- Zhuang Li
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Chun-Xia Yi
- Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Saeed Katiraei
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Sander Kooijman
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Enchen Zhou
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Chih Kit Chung
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
| | - Yuanqing Gao
- Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - José K van den Heuvel
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Onno C Meijer
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Jimmy F P Berbée
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Marieke Heijink
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
| | - Martin Giera
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
| | - Ko Willems van Dijk
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.,Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Albert K Groen
- Department of Vascular Medicine, Amsterdam Diabetes Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.,Department of Pediatrics, University of Groningen, Groningen, The Netherlands
| | - Patrick C N Rensen
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Yanan Wang
- Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.,Department of Pediatrics, University of Groningen, Groningen, The Netherlands
| |
Collapse
|
5
|
Janssen AWF, Katiraei S, Bartosinska B, Eberhard D, Willems van Dijk K, Kersten S. Loss of angiopoietin-like 4 (ANGPTL4) in mice with diet-induced obesity uncouples visceral obesity from glucose intolerance partly via the gut microbiota. Diabetologia 2018; 61:1447-1458. [PMID: 29502266 PMCID: PMC6449003 DOI: 10.1007/s00125-018-4583-5] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2017] [Accepted: 01/22/2018] [Indexed: 02/07/2023]
Abstract
AIMS/HYPOTHESIS Angiopoietin-like 4 (ANGPTL4) is an important regulator of triacylglycerol metabolism, carrying out this role by inhibiting the enzymes lipoprotein lipase and pancreatic lipase. ANGPTL4 is a potential target for ameliorating cardiometabolic diseases. Although ANGPTL4 has been implicated in obesity, the study of the direct role of ANGPTL4 in diet-induced obesity and related metabolic dysfunction is hampered by the massive acute-phase response and development of lethal chylous ascites and peritonitis in Angptl4-/- mice fed a standard high-fat diet. The aim of this study was to better characterise the role of ANGPTL4 in glucose homeostasis and metabolic dysfunction during obesity. METHODS We chronically fed wild-type (WT) and Angptl4-/- mice a diet rich in unsaturated fatty acids and cholesterol, combined with fructose in drinking water, and studied metabolic function. The role of the gut microbiota was investigated by orally administering a mixture of antibiotics (ampicillin, neomycin, metronidazole). Glucose homeostasis was assessed via i.p. glucose and insulin tolerance tests. RESULTS Mice lacking ANGPTL4 displayed an increase in body weight gain, visceral adipose tissue mass, visceral adipose tissue lipoprotein lipase activity and visceral adipose tissue inflammation compared with WT mice. However, they also unexpectedly had markedly improved glucose tolerance, which was accompanied by elevated insulin levels. Loss of ANGPTL4 did not affect glucose-stimulated insulin secretion in isolated pancreatic islets. Since the gut microbiota have been suggested to influence insulin secretion, and because ANGPTL4 has been proposed to link the gut microbiota to host metabolism, we hypothesised a potential role of the gut microbiota. Gut microbiota composition was significantly different between Angptl4-/- mice and WT mice. Interestingly, suppression of the gut microbiota using antibiotics largely abolished the differences in glucose tolerance and insulin levels between WT and Angptl4-/- mice. CONCLUSIONS/INTERPRETATION Despite increasing visceral fat mass, inactivation of ANGPTL4 improves glucose tolerance, at least partly via a gut microbiota-dependent mechanism.
Collapse
Affiliation(s)
- Aafke W F Janssen
- Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, the Netherlands
| | - Saeed Katiraei
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Barbara Bartosinska
- Institute of Metabolic Physiology, Department of Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- Institute for Beta Cell Biology, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), München Neuherberg, Germany
| | - Daniel Eberhard
- Institute of Metabolic Physiology, Department of Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- Institute for Beta Cell Biology, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- German Center for Diabetes Research (DZD), München Neuherberg, Germany
| | - Ko Willems van Dijk
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
- Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Sander Kersten
- Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, Stippeneng 4, 6708 WE, Wageningen, the Netherlands.
| |
Collapse
|
6
|
R. Hoving L, Katiraei S, Heijink M, Pronk A, van der Wee‐Pals L, Streefland T, Giera M, Willems van Dijk K, van Harmelen V. Dietary Mannan Oligosaccharides Modulate Gut Microbiota, Increase Fecal Bile Acid Excretion, and Decrease Plasma Cholesterol and Atherosclerosis Development. Mol Nutr Food Res 2018; 62:e1700942. [PMID: 29665623 PMCID: PMC6001637 DOI: 10.1002/mnfr.201700942] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Revised: 03/15/2018] [Indexed: 12/31/2022]
Abstract
SCOPE Mannan oligosaccharides (MOS) have proven effective at improving growth performance, while also reducing hyperlipidemia and inflammation. As atherosclerosis is accelerated both by hyperlipidemia and inflammation, we aim to determine the effect of dietary MOS on atherosclerosis development in hyperlipidemic ApoE*3-Leiden.CETP (E3L.CETP) mice, a well-established model for human-like lipoprotein metabolism. METHODS AND RESULTS Female E3L.CETP mice were fed a high-cholesterol diet, with or without 1% MOS for 14 weeks. MOS substantially decreased atherosclerotic lesions up to 54%, as assessed in the valve area of the aortic root. In blood, IL-1RA, monocyte subtypes, lipids, and bile acids (BAs) were not affected by MOS. Gut microbiota composition was determined using 16S rRNA gene sequencing and MOS increased the abundance of cecal Bacteroides ovatus. MOS did not affect fecal excretion of cholesterol, but increased fecal BAs as well as butyrate in cecum as determined by gas chromatography mass spectrometry. CONCLUSION MOS decreased the onset of atherosclerosis development via lowering of plasma cholesterol levels. These effects were accompanied by increased cecal butyrate and fecal excretion of BAs, presumably mediated via interactions of MOS with the gut microbiota.
Collapse
Affiliation(s)
- Lisa R. Hoving
- Department of Human GeneticsLeiden University Medical CenterLeiden2300 RCThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical CenterLeiden2300 RCThe Netherlands
| | - Saeed Katiraei
- Department of Human GeneticsLeiden University Medical CenterLeiden2300 RCThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical CenterLeiden2300 RCThe Netherlands
| | - Marieke Heijink
- Center for Proteomics and MetabolomicsLeiden University Medical CenterLeiden2333 ZAThe Netherlands
| | - Amanda Pronk
- Department of Human GeneticsLeiden University Medical CenterLeiden2300 RCThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical CenterLeiden2300 RCThe Netherlands
| | - Lianne van der Wee‐Pals
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical CenterLeiden2300 RCThe Netherlands
- Department of MedicineDivision of EndocrinologyLeiden University Medical CenterLeiden2333 ZAThe Netherlands
| | - Trea Streefland
- Department of MedicineDivision of EndocrinologyLeiden University Medical CenterLeiden2333 ZAThe Netherlands
| | - Martin Giera
- Center for Proteomics and MetabolomicsLeiden University Medical CenterLeiden2333 ZAThe Netherlands
| | - Ko Willems van Dijk
- Department of Human GeneticsLeiden University Medical CenterLeiden2300 RCThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical CenterLeiden2300 RCThe Netherlands
- Department of MedicineDivision of EndocrinologyLeiden University Medical CenterLeiden2333 ZAThe Netherlands
| | - Vanessa van Harmelen
- Department of Human GeneticsLeiden University Medical CenterLeiden2300 RCThe Netherlands
- Einthoven Laboratory for Experimental Vascular MedicineLeiden University Medical CenterLeiden2300 RCThe Netherlands
| |
Collapse
|
7
|
Hoving LR, de Vries MR, de Jong RCM, Katiraei S, Pronk A, Quax PHA, van Harmelen V, Willems van Dijk K. The Prebiotic Inulin Aggravates Accelerated Atherosclerosis in Hypercholesterolemic APOE*3-Leiden Mice. Nutrients 2018; 10:nu10020172. [PMID: 29401645 PMCID: PMC5852748 DOI: 10.3390/nu10020172] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Revised: 01/25/2018] [Accepted: 01/25/2018] [Indexed: 12/19/2022] Open
Abstract
The prebiotic inulin has proven effective at lowering inflammation and plasma lipid levels. As atherosclerosis is provoked by both inflammation and hyperlipidemia, we aimed to determine the effect of inulin supplementation on atherosclerosis development in hypercholesterolemic APOE*3-Leiden (E3L) mice. Male E3L mice were fed a high-cholesterol (1%) diet, supplemented with or without 10% inulin for 5 weeks. At week 3, a non-constrictive cuff was placed around the right femoral artery to induce accelerated atherosclerosis. At week 5, vascular pathology was determined by lesion thickness, vascular remodeling, and lesion composition. Throughout the study, plasma lipids were measured and in week 5, blood monocyte subtypes were determined using flow cytometry analysis. In contrast to our hypothesis, inulin exacerbated atherosclerosis development, characterized by increased lesion formation and outward vascular remodeling. The lesions showed increased number of macrophages, smooth muscle cells, and collagen content. No effects on blood monocyte composition were found. Inulin significantly increased plasma total cholesterol levels and total cholesterol exposure. In conclusion, inulin aggravated accelerated atherosclerosis development in hypercholesterolemic E3L mice, accompanied by adverse lesion composition and outward remodeling. This process was not accompanied by differences in blood monocyte composition, suggesting that the aggravated atherosclerosis development was driven by increased plasma cholesterol.
Collapse
Affiliation(s)
- Lisa R Hoving
- Department of Human Genetics and Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands.
| | - Margreet R de Vries
- Department of Surgery and Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands.
| | - Rob C M de Jong
- Department of Surgery and Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands.
| | - Saeed Katiraei
- Department of Human Genetics and Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands.
| | - Amanda Pronk
- Department of Human Genetics and Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands.
| | - Paul H A Quax
- Department of Surgery and Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands.
| | - Vanessa van Harmelen
- Department of Human Genetics and Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands.
| | - Ko Willems van Dijk
- Department of Human Genetics and Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands.
- Department of Medicine, Division Endocrinology, Leiden University Medical Center (LUMC), 2300 RC Leiden, The Netherlands.
| |
Collapse
|
8
|
Janssen AWF, Houben T, Katiraei S, Dijk W, Boutens L, van der Bolt N, Wang Z, Brown JM, Hazen SL, Mandard S, Shiri-Sverdlov R, Kuipers F, Willems van Dijk K, Vervoort J, Stienstra R, Hooiveld GJEJ, Kersten S. Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids. J Lipid Res 2017; 58:1399-1416. [PMID: 28533304 DOI: 10.1194/jlr.m075713] [Citation(s) in RCA: 78] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2017] [Revised: 05/10/2017] [Indexed: 02/06/2023] Open
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, yet the pathogenesis of NAFLD is only partially understood. Here, we investigated the role of the gut bacteria in NAFLD by stimulating the gut bacteria via feeding mice the fermentable dietary fiber, guar gum (GG), and suppressing the gut bacteria via chronic oral administration of antibiotics. GG feeding profoundly altered the gut microbiota composition, in parallel with reduced diet-induced obesity and improved glucose tolerance. Strikingly, despite reducing adipose tissue mass and inflammation, GG enhanced hepatic inflammation and fibrosis, concurrent with markedly elevated plasma and hepatic bile acid levels. Consistent with a role of elevated bile acids in the liver phenotype, treatment of mice with taurocholic acid stimulated hepatic inflammation and fibrosis. In contrast to GG, chronic oral administration of antibiotics effectively suppressed the gut bacteria, decreased portal secondary bile acid levels, and attenuated hepatic inflammation and fibrosis. Neither GG nor antibiotics influenced plasma lipopolysaccharide levels. In conclusion, our data indicate a causal link between changes in gut microbiota and hepatic inflammation and fibrosis in a mouse model of NAFLD, possibly via alterations in bile acids.
Collapse
Affiliation(s)
- Aafke W F Janssen
- Nutrition, Metabolism, and Genomics Group, Division of Human Nutrition Wageningen University, 6708 WE Wageningen, The Netherlands
| | - Tom Houben
- Department of Molecular Genetics, Maastricht University, 6200 MD Maastricht, The Netherlands
| | - Saeed Katiraei
- Departments of Human Genetics Leiden University Medical Center, 2300 RC Leiden, The Netherlands
| | - Wieneke Dijk
- Nutrition, Metabolism, and Genomics Group, Division of Human Nutrition Wageningen University, 6708 WE Wageningen, The Netherlands
| | - Lily Boutens
- Nutrition, Metabolism, and Genomics Group, Division of Human Nutrition Wageningen University, 6708 WE Wageningen, The Netherlands; Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Nieke van der Bolt
- Nutrition, Metabolism, and Genomics Group, Division of Human Nutrition Wageningen University, 6708 WE Wageningen, The Netherlands
| | - Zeneng Wang
- Department of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195
| | - J Mark Brown
- Department of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195
| | - Stanley L Hazen
- Department of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195
| | - Stéphane Mandard
- Lipness Team-INSERM Research Center UMR1231 and LabEx LipSTIC, Faculté de Médecine, Université de Bourgogne-Franche Comté, 21079 Dijon CEDEX, France
| | - Ronit Shiri-Sverdlov
- Department of Molecular Genetics, Maastricht University, 6200 MD Maastricht, The Netherlands
| | - Folkert Kuipers
- Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Pediatrics and Laboratory Medicine, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands
| | - Ko Willems van Dijk
- Departments of Human Genetics Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Departments of Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
| | - Jacques Vervoort
- Laboratory of Biochemistry, Wageningen University, 6708 WE Wageningen, The Netherlands
| | - Rinke Stienstra
- Nutrition, Metabolism, and Genomics Group, Division of Human Nutrition Wageningen University, 6708 WE Wageningen, The Netherlands; Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Guido J E J Hooiveld
- Nutrition, Metabolism, and Genomics Group, Division of Human Nutrition Wageningen University, 6708 WE Wageningen, The Netherlands
| | - Sander Kersten
- Nutrition, Metabolism, and Genomics Group, Division of Human Nutrition Wageningen University, 6708 WE Wageningen, The Netherlands.
| |
Collapse
|
9
|
Katiraei S, Hoving LR, van Beek L, Mohamedhoesein S, Carlotti F, van Diepen JA, Rensen PCN, Netea MG, Willems van Dijk K, Berbée JFP, van Harmelen V. BMT decreases HFD-induced weight gain associated with decreased preadipocyte number and insulin secretion. PLoS One 2017; 12:e0175524. [PMID: 28445487 PMCID: PMC5406023 DOI: 10.1371/journal.pone.0175524] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 03/27/2017] [Indexed: 01/18/2023] Open
Abstract
Experimental bone marrow transplantation (BMT) in mice is commonly used to assess the role of immune cell-specific genes in various pathophysiological settings. The application of BMT in obesity research is hampered by the significant reduction in high-fat diet (HFD)-induced obesity. We set out to characterize metabolic tissues that may be affected by the BMT procedure and impair the HFD-induced response. Male C57BL/6 mice underwent syngeneic BMT using lethal irradiation. After a recovery period of 8 weeks they were fed a low-fat diet (LFD) or HFD for 16 weeks. HFD-induced obesity was reduced in mice after BMT as compared to HFD-fed control mice, characterized by both a reduced fat (-33%; p<0.01) and lean (-11%; p<0.01) mass, while food intake and energy expenditure were unaffected. As compared to control mice, BMT-treated mice had a reduced mature adipocyte volume (approx. -45%; p<0.05) and reduced numbers of preadipocytes (-38%; p<0.05) and macrophages (-62%; p<0.05) in subcutaneous, gonadal and visceral white adipose tissue. In BMT-treated mice, pancreas weight (-46%; p<0.01) was disproportionally decreased. This was associated with reduced plasma insulin (-68%; p<0.05) and C-peptide (-37%; p<0.01) levels and a delayed glucose clearance in BMT-treated mice on HFD as compared to control mice. In conclusion, the reduction in HFD-induced obesity after BMT in mice is at least partly due to alterations in the adipose tissue cell pool composition as well as to a decreased pancreatic secretion of the anabolic hormone insulin. These effects should be considered when interpreting results of experimental BMT in metabolic studies.
Collapse
Affiliation(s)
- Saeed Katiraei
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Lisa R Hoving
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Lianne van Beek
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Sharida Mohamedhoesein
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Françoise Carlotti
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.,Department of Medicine, division of Nephrology Leiden University Medical Center, Leiden, The Netherlands
| | | | - Patrick C N Rensen
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.,Department of Medicine, division of Endocrinology Leiden University Medical Center, Leiden, The Netherlands
| | - Mihai G Netea
- Department of Internal Medicine, Radboud UMC, Nijmegen, The Netherlands
| | - Ko Willems van Dijk
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.,Department of Medicine, division of Endocrinology Leiden University Medical Center, Leiden, The Netherlands
| | - Jimmy F P Berbée
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.,Department of Medicine, division of Endocrinology Leiden University Medical Center, Leiden, The Netherlands
| | - Vanessa van Harmelen
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.,Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
10
|
van Beek L, Vroegrijk IOCM, Katiraei S, Heemskerk MM, van Dam AD, Kooijman S, Rensen PCN, Koning F, Verbeek JS, Willems van Dijk K, van Harmelen V. FcRγ-chain deficiency reduces the development of diet-induced obesity. Obesity (Silver Spring) 2015; 23:2435-44. [PMID: 26523352 DOI: 10.1002/oby.21309] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Revised: 07/16/2015] [Accepted: 07/30/2015] [Indexed: 01/05/2023]
Abstract
OBJECTIVE Pathogenic immunoglobulins are produced during the development of obesity and contribute to the development of insulin resistance (IR). However, the mechanisms by which these antibodies affect IR are largely unknown. This study investigated whether Fc-receptors contribute to the development of diet-induced obesity and IR by studying FcRγ(-/-) mice that lack the γ-subunit necessary for signaling and cell surface expression of FcγR and FcεRI. METHODS FcRγ(-/-) and wild-type (WT) mice were fed a high-fat diet (HFD) to induce obesity. At 4 and 11 weeks, body weight and insulin sensitivity were measured, and adipose tissue (AT) inflammation was determined. Furthermore, intestinal triglyceride (TG) uptake and plasma TG clearance were determined, and gut microbiota composition was analyzed. RESULTS FcRγ(-/-) mice gained less weight after 11 weeks of HFD. They had reduced adiposity, adipose tissue inflammation, and IR. Interestingly, FcRγ(-/-) mice had higher lean mass compared to WT mice, which was associated with increased energy expenditure. Intestinal TG absorption was increased whereas plasma TG clearance was not affected in FcRγ(-/-) mice. Gut microbial composition differed significantly and might therefore have added to the observed phenotype. CONCLUSIONS FcRγ-chain deficiency reduces the development of diet-induced obesity, as well as associated AT inflammation and IR at 11 weeks of HFD.
Collapse
Affiliation(s)
- Lianne van Beek
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Irene O C M Vroegrijk
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
- Department of Medicine, Division Endocrinology, Leiden University Medical Center, Leiden, the Netherlands
| | - Saeed Katiraei
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Mattijs M Heemskerk
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Andrea D van Dam
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
- Department of Medicine, Division Endocrinology, Leiden University Medical Center, Leiden, the Netherlands
| | - Sander Kooijman
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
- Department of Medicine, Division Endocrinology, Leiden University Medical Center, Leiden, the Netherlands
| | - Patrick C N Rensen
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
- Department of Medicine, Division Endocrinology, Leiden University Medical Center, Leiden, the Netherlands
| | - Frits Koning
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands
| | - J Sjef Verbeek
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands
| | - Ko Willems van Dijk
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
- Department of Medicine, Division Endocrinology, Leiden University Medical Center, Leiden, the Netherlands
| | - Vanessa van Harmelen
- Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands
| |
Collapse
|